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Abstract 
Background: mutation of IDH1 gene is a prognostic factor and a diagnostic hallmark 
of gliomas. Mutant IDH1 enzyme can convert α-KG into 2-Hydroxyglutarate (2HG) 
and mutated gliomas have elevated amounts of intracellular 2HG. Since 2HG is a 
small molecule it seems possible that it could reach the systemic circulation and to be 
excreted by urine. And so, we analyzed 2HG concentration in plasma and urine in 
glioma patients to identify a surrogate biomarker of IDH1 gene mutation.  
Materials and Methods: All patients had a prior histological confirmation of glioma, 
a recent brain MRI (within 2 weeks) showing the neoplastic lesions. The exclusion 
criteria were any chemotherapy performed within 28 days prior, other neoplastic and 
metabolic diseases. Plasma and urine samples were taken from all patients and 2HG 
concentrations determined by liquid chromatography tandem mass spectrometry; 
exon 4 of IDH1 genes were analyzed by Sanger sequencing; differences in metabolite 
concentrations between mutant and wild-type IDH1 patients were examined with the 
Mann-Whitney U test for non-parametric data; Student’s t-test was used to compare 
parametric data. ROC curve was used to evaluate the cut off value of the 2HG 
biomarker. 
Results: 84 patients were enrolled: 38 with IDH1 mutated and 46 IDH1 wild-type. 
All the mutations were R132H. Among patients with mutant IDH1 we had 21 high-
grade gliomas (HGG) and 17 low-grade gliomas (LGG); among patients with IDH 
wild-type we had 35 HGG and 11 LGG.. In all patients we analyzed the mean 2HG 
concentration in plasma (P_2HG), in urine (U_2HG) and the ratio between P_2HG 
and U_2HG (R_2HG).  
	   2	  
We found an important significant difference in R_2HG between glioma patients with 
and without IDH1 mutation (22.2 versus 15.6, respectively, p<0.0001). The optimal 
cut-off value of R_2HG to identify glioma patients with and without IDH mutation 
was 19 (sensitivity 63%, specificity 76%, accuracy 70%); in only PTS with HGG the 
optimal cut-off value was 20 (sensitivity 76%, specificity 89%, accuracy 84%, 
positive predictive value 80%, negative predictive value 86%). No associations 
between the grade or size of tumor and R_2HG were found. In 7 patients with high-
grade gliomas we found a correlation between R_2HG value and response to 
treatment. 
Conclusions: analyzing R_2HG derived from individual plasma and urine 2HG levels 
is possible discriminate glioma patients with and without IDH mutation, in particular 
in high grade gliomas. Moreover, a larger samples need to be analyzed to investigate 
this method in patients follow-up for recurrence detection and to monitor treatment 
efficacy. 
 
 
 
 
 
 
 
 
	   3	  
Abstract 
Background: la mutazione del gene IDH1 rappresenta un importante fattore 
prognostico e diagnostico per i tumori gliali. L’enzima IDH1 avente la mutazione ha 
la capacità di convertire α-KG in 2-Idrossiglutarato (2HG) e i gliomi mutati hanno 
una elevata concentrazione di 2HG all’interno delle cellule tumorali. Poichè 2HG è 
una piccola molecola, tale metabolita potrebbe raggiungere la circolazione sistemica 
ed essere escreta con le urine. Per tale ragione, nel nostro studio abbiamo analizzato la 
concentrazione di 2HG nel plasma e nelle urine nei pazienti con glioma per 
identificare un biomarcatore  surrogato della presenza della mutazione IDH1. 
Materiali e Metodi: per l’arruolamento, tutti i pazienti dovevano avere avuto una 
precedente conferma istologica di glioma, una recente risonanza magnetica cerebrale 
(entro 2 settimane) mostrante la lesione tumorale. Qualsiasi chemioterapia eseguita 
nei 28 giorni precedenti l’analisi del metabolita, la presenza di altre malattie tumorali 
e malattie metaboliche escludevano l’arruolamnto del paziente. Campioni plasmatici e 
urinari sono stati ottenuti da tutti i pazienti e le concentrazioni di 2HG ottenute 
mediante cromatografia liquida-spettrometria di massa; il test di Mann-Whitney è 
stato usato per calcolare le differenze di concentrazione dei metaboliti tra pazienti con 
IDH1 mutato e non-mutato, per dati non parametrici; il test di Student per comparare 
dati parametrici. La curva ROC è stata usata per calcolare il valore di cut-off del 2HG 
come biomarcatore. 
Risultati: sono stati arruolati 84 pazienti: 38 con IDH1 mutato e 46 con IDH1 wild-
type. Tutte le mutazioni sono state R132H. Tra i pazienti con mutazione IDH1 
abbiamo avuto 21 gliomi ad alto grado (HGG) e 17 gliomi a basso grado (LGG). Tra i 
pazienti con IDH1 wild-type abbiamo avuto 35 pazienti con HGG e 11 con LGG. In 
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tutti i pazienti abbiamo analizzato la concentrazione media di 2HG nel plasma 
(P_2HG), nell’urina (U_2HG) e il rapporto tra la concentrazione plasmatica e urinaria 
(R_2HG). E’ emersa una importante differenza statisticamente significativa per 
l’R_2HG tra pazienti con e senza mutazione dell’IDH1 (22.2 verso 15.6, p<0.0001). Il 
cut-off ottimale di R_2HG per identificare lo stato mutazionale di IDH1 nei pazienti 
con glioma è risultato essere 19 (sensibilità 63%, specificità 76%, accuratezza 70%); 
nei soli pazienti con glioma ad alto grado il cut-off ottimale è risultato essere 20 
(sensibilità 76%, specificità 89%, accuratezza 84%, valore predittivo positivo 80%, 
valore predittivo negativo 86%). Non è emersa nessuna associazione tra il grado o la 
dimensione del tumore con il valore di R_2HG. In 7 pazienti con glioma ad alto grado 
analizzati abbiamo, inoltre, trovato una correlazione tra il valore di R_2HG e la 
risposta al trattamento. 
Conclusioni: attraverso l’analisi di R_2HG, derivato dalla concentrazione plasmatica 
e urinaria di 2HG, è possibile discriminare gliomi con e senza mutazione IDH1, 
soprattutto in gliomi di alto grado. Occorrerà analizzare un campione più grande di 
pazienti con glioma per investigare tale metodica anche nel follow up allo scopo di 
individuare precocemente la recidiva di malattia e per monitorare l’efficacia del 
trattamento. 
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INTRODUCTION 
 
Epidemiology and Classification of brain tumors 
Primary malignant brain tumors account for 1.4% of all cancers and are the cause of 
2.4% of all cancer deaths in Western countries(1). The overall average annual age-
adjusted incidence rate for 2005-2009 for primary brain and central nervous system 
(CNS) tumors was 20.5 per 100,000. The overall incidence rate was 5.1 per 100,000 
for children and 26.8 per 100,000 for adults. In addition, the average annual age-
adjusted incidence rates of all primary malignant brain and CNS tumors ranged from 
4.9 to 8.9 per 100,000 and the averaged annual age-adjusted incidence rates of all 
primary non-malignant brain and CNS tumors ranged from 8.9 to 19.02 per 100,000. 
Among adults, the incidence rates ranged from 5.8 to 11.7 per 100,000 for malignant 
tumors and from 11.9 to 25.94 per 100,000 for non-malignant tumors. 
For those with malignant behaviour, the incidence rate was highest for glioblastoma 
(3.19 per 100,000) followed by diffuse astrocytoma (0.58 per 100,000), and 
lymphoma (0.45 per 100,000). Meningioma (7.1 per 100,000), tumors of the pituitary 
(2.93 per 100,000), and nerve sheath (1.69 per 100,000) tumors were the non-
malignant histologies with the highest incidence rates(1). Glioblastomas account for 
16% of all primary brain tumors and are more common in older adults. The incidence 
of glioblastoma increases with increasing age, with rates highest in 75 to 84 years 
olds. Moreover, glioblastomas are 1.6 times more common in males and are two to 
three times higher among whites as compared to black race groups. 
The estimated five-and ten year relative survival rates for malignant brain and CNS 
tumors are 33.8% and 28%, respectively. However, there is a large variation in 
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survival estimates depending upon tumor histologies. For example, five-year survival 
rates are 94% for pilocytic astrocytomas but are less than 5% for glioblastomas. 
Survival generally decreases with older age at diagnosis.  
However, the most common primary malignant brain tumors are of glial origin and 
arise from astrocytes (astrocytomas), oligodendrocytes (oligodendrogliomas), or 
ependymal cells (ependymomas). The World Health Organization (WHO) system is 
the most frequently used classification schema and is based on standard histologic 
criteria(2). According to WHO criteria, up to 80% of gliomas are either WHO grade 
III (anaplastic astrocytoma or oligodendrogliomas) or WHO grade IV 
(glioblastomas). Pilocytic astrocytoma, which occur most commonly in children, are 
considered WHO grade I, and low-grade astrocytomas and oligodendrogliomas are 
considered WHO grade II. Recent studies have reported the median overall survival 
for patients with glioblastoma to be close to 20 months, in contrast to the much longer 
median survival of just over 7 years for patients with low-grade astrocytomas(3).  
In addition to histologic classification of gliomas, interest in the molecular 
characterization of these tumors is increasing. For example, glioblastomas can be 
divided into primary or secondary GBM. Primary GBM tends to occur in older 
patients and is characterized by EGFR amplification, PTEN mutation, and p16 
deletion. Secondary GBM arises from lower grade gliomas and occurs in younger 
patients who have mutation in TP53 and IDH1, PDGFRB overexpression, and 
aberrant signalling of the Rb pathway.  
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Diagnosis 
The signs and symptoms caused by brain tumors are related to their location and rate 
of growth and are therefore quite variable. A rapidly growing relatively circumscribed 
tumor may result in acute focal deficits, whereas a slow-growing diffuse mass can 
cause gradual changes in behaviour or cognition. Intractable headache, new-onset 
seizures, cognitive dysfunction, nausea, and vomiting are frequent accompaniments of 
brain tumors but are not specific, so clinical context remains important. Once a tumor 
is suspected, neuroimaging with contrast-enhanced magnetic resonance imaging 
(MRI) will confirm the presence of a mass lesion. Imaging features such as 
enhancement pattern and location and even additional imaging data such as MRI 
spectroscopy can suggest but not definitively provide a diagnosis, which can be 
obtained only by examination of tissue. 
Treatments for gliomas 
The mainstays of tumor-directed treatment for gliomas include resection, radiation, 
and chemotherapy either alone or in combination, and the choice is based on 
histology, tumor grade, and general medical condition. For some gliomas Level I 
evidence supports a specific therapeutic modality, but treatment decision are often 
based on results from single-arm phase II studies that compare results with historical 
controls. However, recent advances in understanding the molecular genetics of 
gliomas and in the elucidation of tumor-specific prognostic and predictive markers are 
leading the way for development of patient-specific treatment strategies. 
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• Surgery 
The initial therapeutic approach for gliomas is surgery. Surgery not only 
confirms the diagnosis and provides tissue for genetic studies but also can 
improve symptoms by relieving mass effect and edema. Surgery is not 
required in some intrinsic tumors of the brainstem that are not amenable to a 
surgical procedure. Cumulative data suggest that the extent of resection 
impacts outcome for all grade of gliomas: in fact, longer survivals are seen in 
those patients who undergo near total or gross total resection(4). In these 
studies, the extent of resection was usually defined by the presence or absence 
of residual contrast enhancement on MRI taken within 48 hours of resection.  
• Radiation 
Radiation is the most common post-surgical treatment modality for all grades 
of gliomas and is at the times given with concurrent chemotherapy. Radiation 
is delivered to a limited field that targets the area of the lesion and usually a 1 
to 3 cm margin. The total dose delivered increases with glioma grade. For 
glioblastoma, daily fractions of 1.8 to 2 Gy are delivered over 6 weeks for a 
total dose close to and rarely exceeding 60 Gy. Studies have not shown a 
benefit of higher doses or of alternative fraction schedules. 
• Chemotherapy 
Chemotherapy is playing an increasing role in the treatment of gliomas. While 
a large variety of agents have been evaluated, currently the most commonly 
used chemotherapeutic is temozolomide, an oral cytotoxic DNA-alkylating 
agent. The benefit of temozolomide for glioblastoma in particular was shown 
in a phase III trial in which patients with newly diagnosed glioblastoma were 
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randomized after surgery to receive either treatment with external beam 
radiation therapy alone or radiation therapy with concurrent temozolomide(3). 
This study demonstrated that chemoradiation with adjuvant temozolomide 
resulted in a significant improvement in median overall survival compared 
with radiation only (14.6 months versus 12.1 months) and a significant 
increase in 2-year survival (26.5% versus 10.4%).  A recent evaluation of 
these patients demonstrated that the benefit of this regimen lasted throughout 5 
years of follow up(5). A companion study demonstrated that in the subgroup 
of patients whose tumors were shown to have low levels of O6-methylguanine 
DNA methyltransferase (MGMT), the enzyme that repairs DNA damage due 
to temozolomide, overall survival was 46% at 2 years and 14% at 5 years(6). 
Regarding grade III gliomas, those patients with grade III oligodendrogliomas 
have increased response to therapy and length of survival compared with 
patients with grade III astrocytomas. These improved outcomes are strongly 
associated with the loss of heterozygosity of chromosome 1p and 19q, which 
is found in about 80% of cases (7). The deletion is due to an unbalanced 
translocation of 19q to 1p. A recent study demonstrated that patients with 
grade III oligodendroglioma and deletion 1p19q have a longer progression- 
free survival and overall survival when treated with radiation therapy and 
chemotherapy with procarbazine, lomustine and vincristine than patients 
without the deletion(8).   
In the last years, new targeted drugs have been investigated for high grade 
gliomas, such as antiangiogenic drugs (bevacizumab), anti-integrin drug 
(cilengitide), mTOR inhibitors (sorafenib, everolimus) but no drug showed an 
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interesting efficacy but bevacizumab that demonstrated interesting results in 
some phase II studies in recurrent glioblastoma patients(9). To date, a trial is 
ongoing to evaluate the efficacy of bevacizumab as first line treatment with 
radiation therapy and temozolomide in glioblastoma.  
Regarding low grade gliomas, the usefulness of chemotherapy for patients 
progressing after surgery and radiotherapy is well established. PCV 
(Procarbazine, lomustine, vincristine) and temozolomide yield similar 
objective response rates and duration of response (10-24 months), with a 
toxicity profile favouring temozolomide(10). Chemotherapy as initial 
treatment after surgery has been investigated either in association with 
radiotherapy or alone, delaying radiation as consolidation therapy or at tumor 
progression. The studies have included “high-risk patients”, defined by the 
presence of one or more poor prognostic factors, such as age over 40 years, 
large initial tumor volume, presence of residual tumor after resection, 
astrocytic histology, neurological symptoms, and progression on MRI. 
Regarding anaplastic ependymomas, temozolomide alone or in combination to 
cisplatin, can be efficacy(11). 
Predictive and prognostic factors in gliomas 
The WHO classification has various limitations due to the fact that 
classification is still based on subjective criteria, both for phenotype 
determination and grading, and the fact that one histological subtype 
encompasses different molecular subtype with different prognoses. Indeed, it 
is becoming increasingly clear that tumors that share identical histopathologic 
features can actually represent multiple distinct molecular phenotypes. A more 
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detailed molecular understanding of these tumors is thus crucial to improve 
classification, to better predict outcome, to better stratify patients included in 
clinical trials and, finally, to tailor specific treatment to individual tumor types 
or patients. To date, three biomarkers have been identified as potent 
prognostic factors in gliomas: codeletion of chromosome arms 1p and 19q, 
O6-methylguanine-DNA methyltransferase (MGMT), isocitrate 
dehydrogenase (IDH) (12) .  
§ Codeletion of chromosome arms 1p and 19q 
The combined loss of one copy of chromosome arms 1p and 19q occurs in 
the majiority of oligodendrogliomas and anaplastic oligodendrogliomas, as 
well as in important number of oligoastrocytomas and anaplastic 
oligoastrocytomas. This signature is a strong prognostic factors and also a 
predictive factor of response to chemotherapy as well as radiotherapy (7). 
In both low-grade and anaplastic oligodendrogliomas, 1p/19q codeletion is 
predictive of longer progression-free survival and overall survival after 
chemotherapy, radiotherapy or both. The median survival is 12-15 years in 
low-grade oligodendrogliomas and more than 7 years in anaplastic 
oligodendrogliomas with 1p/19q codeletion, versus 5-8 years and 2-3 
years, respectively, in the absence of grade I  (12). The 1p/19q codeletion 
is mutually exclusive with TP53 mutation and EGFR amplification, 
frequently associated with MGMT promoter methylation, and always 
associated with IDH1 or IDH2 mutation. MGMT promoter 
hypermethylation is significantly more frequent and the percentage of 
methylated CpG site was significantly higher in 1p/19q codeletion tumors 
compared with 1p and/or 19q intact. The high frequency of MGMT 
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promoter methylation in 1p/19q codeletion gliomas might partly explain 
their chemosensitivity. Because it is a strong prognostic factor in both low-
grade and anaplastic oligodendrogliomas, and is predictive of response to 
both chemo-and radiotherapy, 1p/19q codeletion is currently used as a 
selection criteria. 
§ O6-methylguanine-DNA methyltranseferase (MGMT) 
O6-methylguanine-DNA methyltransferase is a DNA-repair enzyme that 
removes alkyl groups from O6 position of guanine, one of the most 
frequent sites of DNA alkylation induced by chemotherapeutic agents. By 
suppressing these alkyl groups, MGMT is hypothesized to preclude the 
formation of crosslinks between adjacent strands of DNA, thereby limiting 
the effectiveness of alkylating agents. Based on initial studies in 
glioblastomas and on its biological role, MGMT promoter methylation has 
been initially mostly considered as a predictive factor of response to 
chemotherapy, presumably because MGMT repairs temozolomide-induced 
DNA damage, although this has not been formally demonstrated. In fact, 
recent studies in anaplastic gliomas and glioblastomas showed that MGMT 
promoter methylation is also predictive of better response to radiotherapy, 
suggesting that it may be a marker of better therapeutic response (13).  The 
methylation status of the MGMT promoter was investigated in the EORTC 
clinical trial testing concomitant and adjuvant temozolomide versus 
radiotherapy alone in glioblastoma patients (6). Whatever the treatment, 
MGMT promoter methylation was an independent prognostic factor of 
favourable outcome, and was associated with longer progression-free 
survival and overall survival. The benefit of concomitant and adjuvant 
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temozolomide ro radiotherapy was clear for patients with MGMT 
promoter methylation (overall survival 27.2% at 2 years, 16% at 3 years 
and 9.8% at 5 years, versus 10.9, 4.4 and 3% for patients receiving 
radiotherapy alone, respectively) but not for patients without MGMT 
promoter methylation (5, 6).  
The prognostic impact of MGMT methylation status has also investigated 
in gliomas of lower grades. Surprisingly, MGMT promoter methylation 
was reported to be prognostic but not predictive in anaplastic 
oligodendroglial tumor patients treated with radiotherapy and adjuvant 
PCV versus radiotherapy alone  (14). Similarly, the NOA-04 trial reported 
an important difference in progression-free survival between patients with 
or without MGMT promoter methylation, even when treated with 
radiotherapy alone (15).However, because it is an important prognostic 
and predictive factor in gliomas, ongoing trials use MGMT promoter 
methylation status to stratify patients.  
 
Isocitrate dehydrogenase gene mutations (IDH) 
Mutation of the isocitrate dehydrogenase 1 gene in gliomas is undoubtedly one of the 
most ground-breaking discoveries in the field of neuro-oncology in recent years. 
These mutations were first discovered in a subset of glioblastomas in a study in which 
22 glioblastoma specimens (16). Further analysis of IDH1 in an extended tumor series 
confirmed that IDH1 mutations occurs in 12% of all glioblastomas. The types of 
tumor in which IDH 1/2 mutations prevalently occur are very specific. Among tumors 
of the central nervous system, mutations of IDH are found in approximately 50-90% 
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of adult astrocytomas and oligodendrogliomas of WHO grades II and III, and 
secondary glioblastomas. In contrast, IDH mutations occur only in a small subset (3-
16%) of primary glioblastomas. (17). All reported IDH mutations are missense. 
Almost all IDH1 mutations in gliomas occur at codon 132 encoding arginine (R132), 
with a very rare exception where arginine 100 is replaced with glutamine (R100Q) in 
a few tumors (18). Approximately 90% of all IDH1 mutations are G to A transition at 
the second nucleotide of codon 132 resulting in the substitution of arginine by 
histidine (R132H). Other rare types of IDH1 mutations include substitution of 
arginine with cysteine, serine, glycine, or leucine. Mutations of IDH2 in gliomas are 
much less common than those of IDH1. Mutations of IDH1 and IDH2 are mutually 
exclusive in gliomas, suggesting that the consequences of the mutations in these two 
genes might be equivalent. IDH mutations almost always occur hemizygously.  
Another feature observed in gliomas is that almost all tumors with IDH mutations also 
harbour wither TP53 mutations or total 1p/19q loss.n The concurrent IDH and TP53 
mutations are typically observed in astrocytic tumors of grades II and III and in 
secondary glioblastomas. The combination of IDH mutations and total 1p/19q loss, is 
predominantly found among oligodendrogliomas of grades II and III. Oligoastrocytic 
tumors have either combined TP53 and IDH mutations, or total 1p/19q loss and IDH 
mutations. Because the presence of the TP53 mutation or total 1p/19q loss has long 
been regarded as an indicator of either astrocytic or oligodendroglial tumors and, 
therefore, uniquely contributes to the distinct molecular pathogenesis of these tumors, 
the fact that these two types of tumors always share the same genetic change. This has 
led to the idea that astrocytic and oligodendroglial tumors may share common 
progenitor cells. These cells would first acquire an IDH mutation and subsequently 
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progress either to astrocytomas by obtaining TP53 mutations or to 
oligodendrogliomas by developing total 1p/19q loss (19) (see Figure 1).  
 
Figure 1. Model of development of glial tumors (19).  
Supporting evidence for this theory comes from a study in which a series of paired 
initial and recurrent tumors was screened for the presence of IDH1 mutations, TP53 
mutations, and 1p19q deletions. Four diffuse astrocytomas which initially had IDH1 
mutations alone were found to have developed TP53 mutations at recurrence. 
Likewise, three oligodendrogliomas had 1p19q loss upon recurrence, while retaining 
the same IDH1 mutation that was present initially in the original tumors. No tumor 
has ever been shown to develop IDH1 mutation after acquisition of a TP53 mutation 
or after 1p19q loss. These findings validate the chronological order proposed for the 
genetic events observed, placing IDH1 mutations as the earliest genetic changes 
common to both astrocytic and oligodendroglial tumors (20). 
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There are three isozymes for IDH: IDH1, IDH2 and IDH3. The main function 
common to all isozymes is to catalyze the oxidative decarboxylation of isocitrate into 
α-ketoglutarate (aKG) (17). IDH1 is located in the cytoplasm and peroxisomes where 
it participates in lipid metabolism and glucose sensing. IDH2 and IDH3 are located in 
mitochondria and involved in the Krebs cycle. Mutated IDH1 or IDH2 have 
significantly reduced enzymatic activity in catalysis of conversion of isocitrate to 
aKG, irrespective of the nature of the substituted amino acid (19). The most 
prominent consequence universally acknowledged in all types of IDH mutation is that 
the altered enzyme acquires neomorphic activity to reduce aKG into D-2-
hydroxyglutarate (D-2HG) in an NADPH-dependent manner. The mutant IDH 
produces only D-2HG but not its enantiomer L-2-hydroxyglutarate (21). It was 
demonstrated that 2HG levels are elevated in human gliomas samples; in particular, 
gliomas with wild-type IDH1 had over 100-fold less 2HG (21). Regardless of the 
mechanism, it seems likely that the gain-of-function ability of cells to produce 2HG 
as a result of R132 mutations in IDH1 contributes to tumorigenesis. In turns, hypoxia-
inducible factor (HIF-1) levels increased, which was attributed to release from 
negative regulation by aKG, which is required for prolylhydroxylase activity. 
Prolylhydroxylases promote the degradationof HIF-1. Increased HIF-1 activity has 
been shown to be of great importance in the biology of glioblastoma; moreover, IDH 
enzymes with altered activity profiles may directly or indirectly affect other metabolic 
pathways, including NADP-dependent pathways such as the pentose phosphate 
pathway, intracellular base acid balances, and antioxidant properties (22).  
However, high levels of 2HG have been demonstrated in tumor tissue of glioma 
patients with IDH1 mutation. Since 2HG is a small molecule it seems possible that it 
could reach the systemic circulation and to be excreted by urine and that alterated 
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2HG serum or urine levels may help to identify patients harboring IDH1 mutated 
gliomas. In the study, we analyzed 2HG concentration in plasma and urine in glioma 
patients to identify a biomarker of IDH gene mutation; moreover, we investigated the 
correlation between tumor volume and grade with 2HG concentration in plasma and 
urine. The identification of a reliable biomarker of IDH gene mutation in bodily fluids 
(urine and plasma) would be useful in patients who are not amenable to biopsy 
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MATERIALS AND METHODS 
Patients enrolled in this study development at the Medical Oncology 1 Unit, Venetian 
Oncology Institute – IRCCS, Padua, Italy, must meet the following inclusion and 
exclusion criteria.  
Among inclusion criteria: 
• A prior biopsy of the brain tumor and histological confirmation of glioma 
• Neoplastic tissue available for analysis of IDH1/2 genes by PCR and sequence 
analysis 
• A recent brain MRI (within 2 weeks) showing the neoplastic lesion 
• Written consent 
Among excluxion criteria: 
• Absence of neoplastic lesions on brain MRI 
• Any chemotherapy  performed within 28 days prior 
• Other neoplastic and metabolic diseases 
• Renal and/or liver failure 
Plasma and overnight-urine samples were taken from all the patients. To analyze 
IDH1 gene mutations, DNA isolated from formalin-fixed tumor tissues was subjected 
to PCR using primer pairs specific for exon 4 of IDH1. The amplified products were 
subjected to sequencing analysis by fluorescent capillary electrophoresis (ABI PRISM 
310 genetic analyzer; Applied Biosystem, Carlsbad, California, USA).  
Metabolite concentrations of 2-hydroxyglutarate in urine and plasma were 
determined by liquid chromatography tandem mass spectrometry (LC-MS/MS), at 
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Experimental and Clinical Pharmacology Unit, National Cancer Insitute, Aviano, 
Italy. Differences in metabolite concentrations between mutant and wild-type IDH1 
patients were examined with the Mann-Whitney U test for non-parametric data; 
Student’s t-test was used to compare parametric data. Spearman’s rank correlation 
was used to analyze association between tumor size and metabolite concentration. 
Tumor volume was estimated based on Flair imaging for LGGs and on contrast-
enhanced tumor area for HGGs using the formula for an ellipsoid “π (a x b x c)/6”; 
All p-values were two-tailed, and were considered significant when lower than 0.05. 
The reciver operating characteristic (ROC) curve was performed in order  to 
determine the cut-off value of 2HG biomarker. The optimal cut-off calue was 
determined at the point on ROC curve at which (sensitivity + specificity-1) was 
maximized (Youden Index). 
All statistical analyses were carried out using SPSS statistical software, version 18.0 
(SPSS Inc, Chicago, Illinois, USA). 
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RESULTS 
 
From January 2011 to May 2013 we enrolled 84 patients: 38 patients with mutant 
IDH1 and 46 patients with wild-type IDH1 (see Table 1). 
 
 
 
 
 
 
 
Table 1. Characteristics of patients with mutant and wild-type IDH1. IDH1: isocitrate 
dehydrogenase 1; mut: mutant; wt: wild-type; HGG:high grade gliomas; LGG: low 
grade gliomas. 
 
Among patients with mutant IDH1 we had: 17 females and 21 males; the average age 
was 51 years; 21 patients had high-grade gliomas and 17 had low-grade gliomas; the 
average size of the tumor was 9,2 cm3. The characteristics of the wild-type IDH1 
patients were: 22 females and 24 males, the average age was 62 years; 35 patients 
with high-grade gliomas and 11 patients with low-grade gliomas; the average size of 
the tumor was 38.5 cm3. 
 mut IDH1  wt IDH1  
Number 38 46 
Sex 17 F, 21 M 22 F, 24 M 
Average Age (years) 51 62 
Hystology 21 HGG 
17 LGG 
35 HGG 
11 LGG 
Type of Mutation R132H - 
HGG median volume 2.8 cm3 (0.6-47.1) 3.8 cm3 (0.6-131.9) 
LGG average volume  9.4 cm3 (3.1-81.6) 22 cm3 (6.3-150.7) 
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The concentration of 2HG in plasma was not significantly different between the two 
groups (p=0.9):  the mean 2HG concentration was 97±44.11 ng/mL in patients with 
wild-type IDH1 and 97.2±60.4 ng/mL in the other patients; the median 2HG 
concentration was 80.8 ng/mL (range 45.3-235.0) and 79.1 ng/mL (range 51.2-405.0) 
in patients with wild-type and mutant IDH1, respectively (see Figure 2). 
 
Figure 2. 2HG concentration in plasma in patients with mutant IDH and wild-type 
IDH.  
 
Regarding 2HG concentration in urine (normalized by creatinine concentration), we 
found a statistically significant difference (p=0.002): the mean 2HG concentration 
was 7.3±4.5 µg/mg in patients with wild-type IDH1 and 4.6±2.0 µg/mg in the other 
patients; the median 2HG concentration was 5.6 µg/mg (range 1.8-22.6) and 4.1 
µg/mg (range 2.2-12.3) in patients with wild-type and mutant IDH1, respectively (see 
Figure 3).  
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Figure 3. 2HG concentration in urine in patients with mutant IDH and wild-type IDH  
 
Moreover, we analyzed the ratio between the concentration of 2HG in plasma and 
urine (R_2HG). We found an important difference between the two group (p<0.0001): 
the mean R_2HG concentration was 15.6±6.8 in patients with wild-type IDH1 and 
2.2±8.7 in the other patients; the median R_2HG concentration was 15.1 (range 4.5-
35.4) and 21.1 (range 7.6-42.4) in patients with wild-type and mutant IDH1, 
respectively (see Figure 4).  
 
!
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Figure 4. Ratio between R_2HG concentration in plasma and in urine in all glioma 
patients with mutant IDH and wild-type IDH  
 
Analyzing the metabolite concentration in only 56 patients with high-grade gliomas 
we found that the R_2HG concentration had a higher difference that in all glioma 
patients: the mean R_2HG concentration was 15.3±6.5 in patients with wild-type 
IDH1 and 24.9±9.1 in the other patients; the median R_2HG concentration was 14.9 
(range 4.5-35.4) and 23.1 (range 7.6-42.4) in patients with wild-type and mutant 
IDH1, respectively (see Figure 5).  
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Figure 5. Ratio between R_2HG concentration in plasma and in urine in HGG 
patients with mutant IDH and wild-type IDH  
 
The ROC curve analysis was performed to determine the cut off value of R_2HG. In 
all gliomas patients, the optimal cut-off value of R_2HG to discriminate patients with 
and without IDH1 mutation was 19 with which sensitivity and specificity was 63% 
and 76%, respectively; its accuracy was 70% (see Figure 6).  
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Figure 6. Roc curve analyzing cut-off value of R_2HG in all glioma patients 
 
Analyzing only HGG patients, the optima cut-off value of R_2HG was 20 with which 
sensitivity and specific was 76% and 89%, respectively; its accuracy was 84, positive 
predictive value was 80% and negative predictive value was 86% (see figure 7 and 
Figure 8). 
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 Figure 7. Roc curve analyzing cut-off value of R_2HG in high-grade glioma patients 
	  
Figure 8. Levels of R_2HG in high-grade glioma patients with and without IDH 
mutation. The optimal cut-off value of R_2HG showed in dashed line.  
wt
w
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Subsequently, we performed an analysis of correlation between the tumor size and 
R_2HG in HGG patients with IDH1 mutated (see Figure 9). We demonstrated that 
R_2HG levels are independent of the tumor size (Spearman R= 0.4; p= 0.8).  
 
 
 
 
 
 
 
 
 
Figure 9. Correlation between R_2HG and the tumor size in high-grade patients with 
IDH1 mutated. 
 
We investigated if there is an association between tumor grade and R_2HG in all 
glioma patients. We showed that R_2HG levels are independents of tumor grade; in 
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fact, there is no statistically significant difference of R_2HG among gliomas with 
different tumor grade (p= 0.4) (see Figure 10). 
 
 
Figure 10.  Analysis of R_2HG in LLG and HGG patients with IDH mutated. LGG= 
low grade glioma; HGG= high grade glioma. 
 
Finally, we analyzed in a few patients the levels of R_2HG before and after the 
chemotherapeutic treatment; in particular, we performed a gadolinium-brain magnetic 
resonance imaging (MRI) before and after the treatment and correlated the R_2HG 
levels to the MRI response evaluated according to RANO criteria.  A valid biomarker 
should increase in case of progression disease on MRI and should decrease in case of 
partial or complete response on MRI.  
	   !
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We analyzed 7 patients with HGG and 4 patients with LGG. 
Among patients with HGG we had: 4 partial responses, 1 complete response and 2 
progression diseases. In all cases of response we had a decrease of R_2HG, while in 
both the cases of progression disease the biomarker was increased (see Figure 11). 
 
 
Figure 11. Difference of R_2HG value before and after the chemotherapeutic 
treatment and its correlation with response on brain-MRI in seven patients with high-
grade gliomas 
 
Among patients with LGG we had: 3 partial responses and 1 stable disease. Unlike 
the high-grade gliomas, in these patients there were discordance between response on 
MRI and levels of R_2HG; in fact, in one case of partial response the biomarker was 
increased while in the other two cases the biomarker was decreased; in the patient 
with stable disease the biomarker was increased slightly.    
	  
Progression 
disease 
Partial/Complete 
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DISCUSSION 
 
Gliomas comprise the second most common primary central nervous system 
neoplasms, behind meningiomas, and account for 80% of primary, malignant brain 
tumors (1).  
Gliomas are classified by the resemblance of the neoplastic cells to normal glial types, 
and in the current WHO classification include those of astrocytic lineage, 
oligodendroglial lineage and those showing mixed lineage (oligoastrocytomas) (2). 
WHO classification of gliomas is based on a grading scheme from II to IV based on 
histomorphology, proliferation, and the presence of microvascular proliferation or 
necrosis; however, this classification has limitations; in particular, classification and 
grading of gliomas is accompanied by a considerable interobserver variation (23) and 
moreover, significant heterogeneity in clinical behavior among tumors with the same 
grade and clinical features is observed.  
In the last years, it is becoming evident that gliomas can be separated into well 
characterized prognostic groups based on molecular profiling (24). 
The recent discovery that genes encoding IDH1 and IDH2 can be mutated in gliomas 
represents one of the biggest success stories for cancer biology. The most frequent 
mutations affect codon 132 in IDH1 and 172 in IDH2. These mutations occur in 70-
80% of grade II and III astrocytomas, oligodendrogliomas, oligoastrocytomas and 
secondary glioblastomas (25). Mutant IDH enzymes show a neomorphic enzymatic 
capacity to convert α-KG into 2HG, a small oncometabolite; in fact, 2HG inhibits α-
KG binding to several histone demethylases leading to a widely aberrant histone 
modification profile, particularly histone tail methylation. 2HG also inhibits the TET 
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oncogene 1 and 2 hydroxymethylases; finally, 2HG can decrease levels of HIF-1 
antagonist endostatin increasing VEGF (vascular endothelial growth factor) signaling 
(26).  
Various studies demonstrated that gliomas of grade II-IV carrying IDH mutations 
have a better prognosis than IDH wild-type tumors (15, 27-29) and so, IDH mutation 
status should be added to current WHO classification. Moreover, enzymes defects are 
attractive molecule for targeted therapy such as restoring normal IDH function, 
replacing depleted α-KG or deplecing 2HG; and so, the presence of IDH mutations 
may have a predictive factor, as well. Most interestingly, a selective R132H-IDH1 
inhibitor has recently been shown to specifically impair the growth of IDH1-mutant 
glioma cells and promote their differentiation (30).  
The assessment of IDH status can be used as a diagnostic marker, as well. In fact, the 
presence of IDH mutation can recognize diffuse tumor infiltration of astrocytoma or 
oligodendroglioma, identify residual glioma cells in tissue with extensive post-
therapy changes, distinguish diffuse tumor infiltration from reactive gliosis, 
distinguish diffuse astrocytomas as opposed to pilocytic astrocytoma (WHO grade I), 
distinguish astrocytic and oligodendroglial tumors from ependymomas, distinguish 
oligodendrogliomas from other glioneural tumors.  
Currently available methods of detecting IDH mutations in gliomas are based on 
analysis of glioma tissue investigating either the altered structure of the protein, by 
monoclonal antibody against the common mutation IDH1 R132H, or the sequence of 
the IDH gene by gene sequencing. The sensitivity and specificity of monoclonal 
antibody for detecting IDH1 R132H reportedly approaches 100% (31) although the 
other rare mutations are not detected. While gene sequencing can identify all possible 
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mutations within the region amplified, the sensitivity of this method is about 20% of 
mutant sequences in a wild-type background, and so the mutant template must 
represent a relatively high proportion of the tissue to allow detection (32, 33).  
Noteworthy, not all patients with gliomas can be amenable to biopsy because of their 
poor performance status or localization of the lesion in sensitive areas, such as the 
brainstem. An interesting non-invasive method to identify IDH status mutation was 
described by Sanson et al (34); they extracted small-size DNA (150-250 base pairs) 
from the plasma and IDH-R132H mutation was detected by a combination of 
coamplification at lower denaturation temperature and digital PCR; The IDH-R132H 
mutation was detected in 15 out of 25 plasma DNA mixtures (60%) from patients 
with mutated tumors and in none of the 14 patients with a non-mutated tumor. The 
specificity was 100% while the sensitivity was related to the tumor volume: 33% in 
non-enhancing tumors, 60% for enhancing volume <10cm3, and 100% (6/6) for 
enhancing volume ≥10cm3. And so, this method can be used in gliomas with large 
contrast enhancement while other methods have to be used for low grade gliomas, 
such as the analysis of 2HG detection by magnetic resonance spectroscopy (35) with a 
sensitivity of 100% and a 26% of false positive rate in the detection of 2HG; in fact, 
2HG is 100-fold increased in glioma cells with IDH mutations (21) and the non-
invasive detection of increased 2HG levels may serve as a surrogate marker for 
various type of IDH mutations.. Since 2HG is a small molecule it seems possible that 
it could reach the systemic circulation and to be excreted by urine, as showed in 
patients with 2-hydroxyglutaric aciduria, a metabolic disease due to 2HG 
dehydrogenase gene mutations (36). And so, we evaluated whether 2HG levels in 
urine and plasma may correlate with IDH mutation status. As described by a prior 
study (37), we found no statistical difference in plasma concentration between 
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patients with and without IDH1 mutation. For the first time worldwide, we analyzed 
the 2HG levels in urine in patients with gliomas and surprisingly, we found that 
patients with IDH1 mutation have a lower 2HG concentration than patients lacking 
the mutation. IDH1 mutation generate D-enantiomer of 2HG and not the L isomer of 
2HG (21); likely, these isomers may have a different time of excretion by urine 
resulting in a lower concentration of urinary 2HG in patients with IDH mutations 
because of excess accumulation of the enantiomer D-2HG. Noteworthy, the ratio 
between 2HG concentration in plasma and urine was significantly higher in patients 
with IDH1 mutation and especially, in patients with high-grade gliomas, probably 
reflecting a disruption in the blood-brain barrier. We found that the optimal cut-off 
value to discriminate the IDH mutation status in high-grade gliomas was 20 with an 
important sensitivity, specificity and accuracy; in particular, this cut-off has a high 
negative and positive predictive value (86% and 80%, respectively). On the other side, 
we did not find a correlation between tumor size or tumor grade and R_2HG levels.  
Although we analyzed only 7 patients with high-grade glioma, we showed that 
detection of R_2HG may provide a method to follow up disease progression in these 
patients with IDH1 mutant tumor and to monitor treatment effects; however, a large 
prospective study should be planned to clarify this aspect.  
In conclusion, the presence of IDH1 mutation represents a valid prognostic and 
diagnostic marker for glioma patients; moreover, in the future it might predict 
efficacy of therapies targeted against this alteration. So, the identification of a reliable 
surrogate biomarker of IDH1 mutation in accessible bodily fluids would be useful, in 
particular in patients who are not amenable to biopsy. We demonstrated that the ratio 
between 2HG levels in plasma and urine can be used as a biomarker to differentiate 
glioma patients with and without IDH mutation, especially in patients with high-grade 
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gliomas. Moreover, a larger samples need to be analyzed to investestigate this method 
in patients follow-up for recurrence detection and to monitor treatment efficacy. 
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